Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel
NASDAQ:SABSW

SAB Biotherapeutics Earnings Date & Estimates

SAB Biotherapeutics logo
$0.0011 0.00 (0.00%)
As of 10/23/2026

SAB Biotherapeutics is estimated to report earnings on Tuesday, November 17, 2026, before market opens.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from SAB Biotherapeutics

SAB Biotherapeutics is expected to post earnings of -$0.2746 per share on revenue of $125 thousand.

Consensus Estimates

Consensus EPS
-$0.2746
Expected Revenue
$125 thousand

Prepare for the Earnings Call

SAB Biotherapeutics Earnings FAQ

SAB Biotherapeutics (NASDAQ:SABSW) is estimated to report earnings on Tuesday, November 17, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect SAB Biotherapeutics to post earnings of -$0.2746 per share for the quarter.

The consensus revenue estimate for SAB Biotherapeutics is $125 thousand for the quarter.

SAB Biotherapeutics Earnings Headlines

No headlines for this company have been tracked by MarketBeat.com
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email.

About SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ:SABSW) is a clinical-stage biotechnology company developing antibody-based medicines. Its proprietary platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company researches for potential use against autoimmune diseases and infectious illnesses.

The company’s pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes, and SAB-185, an antibody treatment studied for infectious diseases. These are developmental programs, not established marketed products.

Founded in 2014 and based in Sioux Falls, South Dakota, SAB Biotherapeutics became a publicly traded company through a merger with Big Cypress Acquisition Corp. in 2021. Co-founder Eddie Sullivan has served as the company’s chief executive officer.

View SAB Biotherapeutics Profile
Earnings Tools